Literature DB >> 3428357

Selective blockade in vivo of cardiac muscarinic M2 receptors by a polymethylene tetramine, BHC-9C.

J Wess1, G Lambrecht, E Mutschler, C Melchiorre, P Angeli.   

Abstract

The antimuscarinic effects of BHC-9C (N,N'-bis[6-[(2-methoxybenzyl)amino]hexyl]-1,9-nonanediamine tetrahydrochloride), a member of a series of polymethylene tetraamines with unprecedented in vitro selectivity for cardiac muscarinic M2 receptors, were assessed in several in vivo test systems. BHC-9C (300 micrograms/kg i.v.) proved to be a potent antagonist at cardiac M2 receptors that mediate the decrease in heart rate in the pithed rat. In contrast, it displayed no considerable blocking activity at vascular M2 receptors subserving vasodepression and at ganglionic M1 receptors that mediate cardiovascular stimulation in the anaesthetized and pithed rat, respectively. These in vivo data are consistent with the suggestion based on in vitro experiments that BHC-9C is a highly selective antagonist of cardiac muscarinic M2 receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428357     DOI: 10.1016/0014-2999(87)90092-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo.

Authors:  J Wess; P Angeli; C Melchiorre; U Moser; E Mutschler; G Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

2.  Selective blockade of muscarinic M2 receptors in vivo by the new antagonist tripitramine.

Authors:  P Angeli; F Cantalamessa; U Gulini; C Melchiorre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-09       Impact factor: 3.000

3.  The contributions of muscarinic receptors and changes in plasma aldosterone levels to the anti-hypertensive effect of Tulbaghia violacea.

Authors:  Ismaila Raji; Pierre Mugabo; Kenechukwu Obikeze
Journal:  BMC Complement Altern Med       Date:  2013-01-11       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.